This article explores the pharmacologic rationale for monitoring hourly vital signs and the subsequent effects of disturbances in sleep patterns in the patient who receives a constant infusion of IV NTG. Although some patients may require additional vasoactive drugs to maintain stability of vital signs, this article addresses the monitoring practices for IV NTG in patients with acute MI, unstable angina, or CHF who do not require other vasoactive drugs.

You do not currently have access to this content.